Skip to main content
. 2020 Oct 16;21(20):7649. doi: 10.3390/ijms21207649

Figure 5.

Figure 5

Protein expression investigation by Western blot upon treatment with selumetinib and/or BEZ235. (a) For c-/PARP and PCNA detection 100nM selumetinib (S) and/or 10nM BEZ235 (B) was applied for 48 hours. Apoptosis induction (c-PARP) was detected upon treatment with selumetinib and selumetinib + BEZ235 in case of A375 and WM239. Decreased expression of PCNA upon selumetinib or combination treatment was detected in A375 and WM239 cells. (b) For signaling pathway element detection (Akt, Erk, S6), 50nM of selumetinib, 5nM of BEZ235 or the combination of them was used for 4 hours. In all four cell lines, S6 and Erk activation decreased upon treatment with BEZ235/selumetinib + BEZ235 and selumetinib/selumetinib + BEZ235, respectively. However, Akt activation decrease was detected only in case of SW1417 cell line. Blots are representative pictures from three independent experiments.